Synchrony Financial: Don't Fear Tighter Credit Standards
Synchrony Financial experienced lower loan growth in preparation for a rule limiting late fees. Nevertheless, core 2025 EPS ...
Synchrony Financial expects 2025 net revenue to fall amid moderate consumer spending
Synchrony Financial said on Tuesday it expects lower net revenue for 2025 as spending levels moderate and interest rates dip, ...
Synchrony Financial stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
Synchrony Financial stock underperforms Monday when compared to competitors
Synchrony Financial closed 1.51% below its 52-week high of $70.93, which the company reached on January 23rd.
Synchrony Financial (NYSE:SYF) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript January 28, 2025 Synchrony Financial misses on earnings expectations. Reported EPS is $1.91 ...
Synchrony Financial's SWOT analysis: stock resilience amid regulatory challenges
Synchrony Financial (NYSE: NYSE:SYF), a leading consumer financial services company, has demonstrated remarkable resilience in the face of regulatory challenges and economic uncertainties. As of ...
Synchrony Financial: Strategic Credit Tightening Amid Industry Challenges Warrants Hold Rating
BTIG analyst Vincent Caintic has maintained their neutral stance on SYF stock, giving a Hold rating yesterday.Invest with Confidence: Follow ...
American Banker1d
Synchrony takes hit from investors after charge-offs rise
Synchrony Financial's fourth-quarter earnings results missed analysts' forecasts and investors pummeled the stock due to a ...
Positive Outlook for Synchrony Financial Despite Earnings Miss: Strong Credit Metrics and Strategic Actions Drive Buy Rating
Synchrony Financial (SYF – Research Report), the Financial sector company, was revisited by a Wall Street analyst yesterday. Analyst Donald ...
Synchrony Financial Q4: Earnings Miss, Lower Purchase Volume, Active Accounts Decline And More
Synchrony Financial reported Q4 results with a Y/Y increase in net interest income, driven by higher interest and fees on ...
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Synchrony Reports Fourth Quarter 2024 Results
Synchrony Financial (NYSE: SYF) today announced its fourth quarter 2024 results for the period ending December 31, 2024. The earnings news release and presentation can be found on the company's invest ...